

To: Purdue Field Sales
From: Managed Markets Marketing
Bulletin Number: 213
Date: 11/03/16



FAVORABLE CHANGE

IMPORTANT FORMULARY UPDATE FOR BUTRANS®

Effective: 1/1/17

As of January 1, 2017, Butrans will be unrestricted preferred on all of Cigna's commercial formularies at the lowest brand co-pay. More than 6 million commercial lives will now have Butrans available at the preferred brand co-pay of approximately \$30. Previously, Cigna had Butrans in a non-preferred position.

Belbuca will remain in a non-preferred/Not covered position. In addition to the co-pay disadvantage, patients with a Belbuca prescription will have to try and fail Butrans before Cigna will allow it to go through.

Your Regional Account Executive will set up additional District conference calls to provide access messaging, business insights and to build out your pull-through action plans.

As always, contact your District Business Manager or Regional Account Executive with questions.

Butrans® Unrestricted Preferred for Cigna Commercial

Please review the overall formulary status for Butrans® to consider during your conversations with healthcare providers. Remember to use your Dynamic Access Messaging customized formulary grids and to remind the healthcare providers that inclusion on formulary does not imply superior clinical efficacy or safety.

To: Purdue Field Sales
From: Managed Markets Marketing
Bulletin Number: 213
Date: 11/03/16



FAVORABLE CHANGE

Plan, Benefit Design, and Formulary	Cigna Commercial formulary for Butrans®
Tier	Preferred Unrestricted
Co-pay Amount	~\$30
Prior Authorization	NA
Quantity Limit	30 tabs per month/1 tab per day
Step Therapy	NA
Limitations	NA
Grandfathering	NA
Prescriber Specialty	NA
Authorization Period	NA
Criteria to Bypass Restriction(s)	NA
Other	NA

If you have immediate questions, please contact your manager or your Regional Account Executive.